Dr. Reddy’s Laboratories Ltd. has launched Toripalimab, branded as Zytorvi®, in India, a move set to reshape the oncology treatment market. The drug, approved by major global regulatory bodies like the USFDA, EMA, and DCGI, is the first immuno-oncology option for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Demonstrating a 48% reduction in the risk of progression or death when used with chemotherapy, Toripalimab addresses an urgent market gap in cancer care.
India, with a high burden of NPC, especially in the northeastern states, represents a promising market for advanced cancer treatments. In Kolkata, a key healthcare hub in Eastern India, the launch is expected to boost demand for innovative therapies. As the region continues to invest in medical infrastructure, Toripalimab’s availability aligns with the growing need for specialized oncology treatments. This will likely drive significant market growth, as more patients seek access to advanced, life-saving medications.
M.V. Ramana, CEO of Branded Markets, highlighted, “Toripalimab’s launch is pivotal in meeting the critical unmet need in India, offering superior outcomes for NPC patients.”Dr. Reddy’s strategic entry into the Indian market, following its successful global launch, positions the company to capitalize on India’s expanding oncology market, with a focus on emerging regions like Kolkata.